Stock Markets
Moldovan official accuses Russia of meddling in Sunday’s presidential runoff
By Tom Balmforth and Felix Hoske
CHISINAU (Reuters) -A Moldovan security official accused Russia on Sunday of “massive interference” as Moldovans voted in a tightly fought presidential election that could see Moscow claw back influence in a country drawing closer to the European Union.
Pro-Western incumbent Maia Sandu, who has accelerated the nation’s push to leave Moscow’s orbit and join the EU, faces Alexandr Stoianoglo, an ex-prosecutor general backed by the traditionally pro-Russian Socialist Party.
The fortunes of Sandu, who set Moldova on the long path of EU accession talks in June, is being closely watched in Brussels a week after Georgia, another ex-Soviet state seeking membership, re-elected a ruling party regarded in the West as increasingly pro-Russian.
The future of Moldova, a poor agricultural nation of fewer than 3 million people, has been in the spotlight since Russia began its full-scale invasion of neighbouring Ukraine in 2022.
“We’re seeing massive interference by Russia in our electoral process … an effort with high potential to distort the outcome,” Sandu’s national security adviser Stanislav Secrieru wrote on X.
There was no immediate comment from Moscow, which has denied past allegations of meddling. Moldova has accused Ilan Shor, a fugitive oligarch living in Russia, of spending millions of dollars to pay off voters to oppose Sandu. He denies wrongdoing.
Stoianoglo says he supports EU integration, but also wants to develop ties with Russia in the national interest. He wants to renegotiate cheap Russian gas supplies and said he would meet with President Vladimir Putin if Moldovans wanted it.
“I voted for a free, stable and blossoming Moldova that isn’t standing with its hand out, but develops in harmony based on relations with the West and East,” he said after casting his ballot.
Polling stations close at 9 p.m. (1900 GMT). Early results will start coming in an hour later, but they will change, possibly significantly, as they are updated with the vote from larger cities like Chisinau and the diaspora abroad.
The results will set the tone for parliamentary elections next year when Sandu’s party may struggle to retain its majority.
“Today is a crucial day for us… we go in one direction or the other. We didn’t have such an important day in the last 30 years,” said Mihai David, 58, who voted in Chisinau.
“My son is in Germany, and I’m happy about it. I was there and it’s much better and we want it to be the same here,” said Maria Fefilova, 68, a pensioner.
Stoianoglo’s East-West balancing rhetoric contrasts with Sandu’s four years in power, during which ties with the Kremlin have unravelled, Moscow’s diplomats have been expelled and she has condemned Russia’s invasion of Ukraine. Moscow calls her government “Russophobic”.
Sandu portrays Stoianoglo as the Kremlin’s man and a political Trojan horse, painting Sunday’s vote as a choice between a bright future in the EU by 2030 or one of uncertainty and instability.
Stoianoglo says that is untrue and that Sandu has failed to look out for the interests of ordinary Moldovans. He accuses her of divisive politics in a country that has a Romanian-speaking majority and large Russian-speaking minority.
MEDDLING ALLEGATIONS
Security official Secrieru cited reports of Moldovans being transported to vote in an organised and therefore illegal way from Moldova’s pro-Moscow breakaway region of Transdniestria where Russia has soldiers stationed as peacekeepers.
Voters there have to travel to Moldovan-controlled territory to vote, but do so under their own steam. By 11 a.m., turnout for the region was already higher than it was for the whole of the first round on Oct. 20, Secrieru said.
He said people had also been brought by organised group transport from Russia and taken by bus and on large charter flights to Moldovan polling stations abroad in Baku, Istanbul and Minsk.
There had also been coordinated cyberattacks targeting the connectivity of voter record systems and disrupting links between polling stations domestically and abroad, he said.
The police have cracked down to try to avoid a repeat of what they said was a vast vote-buying scheme deployed by Shor in the first round and a referendum on the EU’s aspirations that was held the same day.
Sandu has said the meddling affected the Oct. 20 results and that Shor sought to buy the votes of 300,000 people, more than 10% of the population. The referendum delivered a slender win of 50.35% for the pro-EU camp. Sandu won 42% of the vote in the first round. Stoianoglo came second with 26%.
A Moldovan government source said Chisinau notified several EU nations that it believed Russia would try to disrupt voting by expatriates at polling stations in their countries on Sunday. Moldovans living in the West are typically pro-European and more likely to support Sandu.
Secrieru said four bomb hoaxes had been reported to polling stations in Britain’s Liverpool and Northampton and Germany’s Frankfurt and Kaiserslautern.
Stoianoglo is expected to benefit from protest votes against Sandu’s handling of the economy. Moldova struggled with the aftermath of the COVID pandemic and the effects of Russia’s Ukraine invasion, which sparked a huge influx of refugees and sharply reduced Russian gas supplies, causing high inflation.
In Gagauzia, a largely pro-Russian autonomous region, a dozen voters polled by Reuters outside a polling station suggested or said outright that they voted for Stoianoglo.
“We’re a neutral country and we don’t need the European Union. For the last four years, we haven’t seen anything from our president… The prices are high, everything is expensive, everything,” said Dmitry, 57, a communal worker.
On Monday, Truist Securities revised its price target for Editas Medicine (NASDAQ:), a company specializing in gene editing technology. The firm reduced the target to $8.00 from the previous $12.00 while retaining a Buy rating on the stock.
The adjustment follows the company’s third-quarter report, which did not present any unexpected results following recent announcements. The analyst indicated that Editas Medicine is expected to provide updated data on its reni-cel therapy at the upcoming American Society of Hematology (ASH) meeting, as well as updates on its in vivo program in the first quarter of 2025.
The reassessment of the reni-cel program prompted the analyst to moderate the outlook, leading to the lowered price target. Despite this change, the firm continues to support a Buy rating for Editas Medicine shares, suggesting confidence in the company’s long-term potential.
Editas Medicine is actively engaged in the development of gene-editing therapies, with reni-cel being one of its key investigational treatments. The forthcoming data presentations are anticipated to shed more light on the progress and efficacy of these treatments.
The updated price target of $8.00 reflects a more conservative valuation of Editas Medicine by Truist Securities, while the maintained Buy rating indicates a positive view of the stock’s future performance despite the recent adjustments.
In other recent news, Editas Medicine has been the focus of several analyst adjustments. Wells Fargo reduced its price target for Editas from $27.00 to $9.00, while maintaining an Overweight rating. This adjustment followed Editas Medicine’s disclosure of preclinical data for its in vivo hematopoietic stem and progenitor cell (HSPC) editing program.
The company also announced its intention to partner or out-license its reni-cel therapy. Baird also lowered its target for Editas Medicine to $10 from $18, keeping an Outperform rating.
The company has made significant strides in gene editing treatments for sickle cell disease and beta-thalassemia. It reported high levels of editing in hematopoietic stem and progenitor cells. Additionally, Editas secured an upfront payment of $57 million from a financing agreement with DRI Healthcare Trust. Leerink Partners and Truist Securities maintained their Market Perform and Buy ratings respectively on Editas’ stock.
InvestingPro Insights
Recent financial data from InvestingPro provides additional context to Truist Securities’ revised outlook on Editas Medicine (NASDAQ:EDIT). The company’s market capitalization stands at $245.89 million, reflecting its current valuation in the biotech sector. Editas’ stock has experienced significant volatility, with a 41.8% price decline over the past three months and a 48.68% drop in the last six months, aligning with the analyst’s more cautious stance.
InvestingPro Tips highlight that Editas is quickly burning through cash and is not expected to be profitable this year, factors that likely influenced Truist’s decision to lower the price target. The company’s gross profit margin is weak, with a negative 165.65% for the last twelve months as of Q2 2024, underscoring the challenges in its developmental stage.
Despite these headwinds, Editas maintains a strong liquidity position. An InvestingPro Tip notes that the company’s liquid assets exceed short-term obligations, providing some financial flexibility as it advances its gene-editing therapies. This could be crucial as Editas prepares to present updated data on reni-cel and its in vivo program.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for Editas Medicine, providing deeper insights into the company’s financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Cemex SAB de CV (NYSE:), a leading materials company in the construction industry, has seen its stock price touch a 52-week low, dipping to $5.17. This price level reflects a significant downturn from its previous positions, marking a challenging period for the company. Over the past year, Cemex’s stock has experienced a notable decline, with a 1-year change showing a decrease of 22.42%. This downturn is indicative of the broader pressures facing the construction sector, including fluctuating demand and cost pressures, which have impacted the company’s market valuation and investor confidence.
In other recent news, CEMEX has reported a year of substantial growth and strategic optimization despite facing natural disasters and undergoing significant divestitures. The company announced divestitures amounting to $2.2 billion, concentrating on operations in the Dominican Republic, Guatemala, and the Philippines. In spite of severe weather conditions, including three major hurricanes in the U.S., CEMEX achieved a net income increase of over 200% year-over-year.
CEMEX’s growth strategy, initiated in 2019, has resulted in a 14% compound annual growth rate (CAGR) since 2020. The company also reported a 3% reduction in Scope 1 emissions and received a €157 million grant from the EU for a carbon capture project in Germany.
Analysts from Thompson Davis and Goldman Sachs questioned the company’s valuation strategies and the impact of Mexican residential demand on CEMEX, respectively. In response, CEMEX executives emphasized careful evaluation of operational changes and positive expectations for significant impact starting in 2025.
These are among the recent developments that underline CEMEX’s resilience and strategic focus, allowing it to navigate a challenging environment while maintaining a positive outlook for growth.
InvestingPro Insights
Cemex’s recent stock performance aligns with several key insights from InvestingPro. The company is currently trading near its 52-week low, as reflected in the article, with InvestingPro data showing the stock price at $5.18 at the previous close. This represents just 56.02% of its 52-week high, underscoring the significant downturn mentioned.
Despite the challenging market conditions, InvestingPro Tips highlight that Cemex remains a prominent player in the Construction Materials industry. The company’s Price to Book ratio of 0.63 suggests it may be undervalued relative to its assets, potentially offering value for investors looking beyond current market sentiment.
Importantly, an InvestingPro Tip indicates that net income is expected to grow this year, which could provide a positive catalyst for the stock. This growth expectation, combined with the company’s low valuation multiples, may present an opportunity for investors willing to weather the current downturn.
For those seeking a more comprehensive analysis, InvestingPro offers 7 additional tips that could provide further insights into Cemex’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
On Monday, Jefferies adjusted its stance on shares of Booz Allen Hamilton (NYSE:), downgrading the stock from Buy to Hold, though the firm increased the price target to $190 from $180. The revision comes despite acknowledging the company’s strong management and share price performance.
The analyst from Jefferies noted that while Booz Allen Hamilton has shown stellar performance, a pause on the stock is suggested as earnings per share (EPS) revisions through the fiscal year 2025 (ending in March 2025) may be limited.
The limited potential for EPS revisions is attributed to margins being range-bound, with the Defense sector—accounting for 48% of sales and approximately 10% margins—outperforming the Civil sector, which makes up 33% of sales and has a 13% margin. The analyst further pointed out that there is an anticipated slowdown in organic growth excluding items, from 11% in the fiscal year 2025 to 8% in fiscal years 2026 to 2027 estimates.
The new price target of $190 is based on a 30% market premium or twice the three-year average, reflecting the analyst’s valuation of the stock. This price target suggests a modest upside from the previous target, indicating a positive outlook on the company’s value despite the rating downgrade.
The downgrade to Hold reflects a cautious approach towards Booz Allen Hamilton’s stock, considering the expected limitations in earnings growth and margin expansion in the upcoming years. The firm’s analysis suggests that while the company has been performing well, future gains might not be as robust as in the previous periods.
In other recent news, Booz Allen Hamilton reported a robust second quarter for fiscal year 2025, with major revenue hikes in its civil, defense, and intelligence sectors.
The company’s VOLT growth strategy, a record $41 billion backlog, a $115 million insurance recovery, and a $200 million boost from payroll modernization were significant contributors to this performance. Adjusted EBITDA reached $364 million, a 25% year-over-year increase, and net income surged by 129% to $390 million.
Despite the loss of the Advana contract and a Department of Veterans Affairs contract to Deloitte, Booz Allen maintains a strong demand environment with a qualified pipeline of over $20 billion.
The firm’s operating model allows for quick adaptation to client needs amid shifting priorities, and recruitment and retention trends remain strong, making Booz Allen an attractive destination for tech talent. These recent developments emphasize Booz Allen’s strong market presence and potential for continued growth.
InvestingPro Insights
While Jefferies has downgraded Booz Allen Hamilton (NYSE:BAH) to Hold, recent data from InvestingPro paints a nuanced picture of the company’s financial health and market performance. BAH’s revenue growth of 13.94% over the last twelve months and a strong 18.01% quarterly growth align with the company’s solid performance noted in the article.
The stock’s P/E ratio of 28.58 and an adjusted P/E ratio of 31.27 for the last twelve months as of Q2 2025 suggest that investors are willing to pay a premium for BAH’s earnings, which could be justified by its consistent growth. This valuation is further supported by the company’s robust EBITDA growth of 30.89% over the same period.
InvestingPro Tips highlight that BAH has raised its dividend for 9 consecutive years and maintained payments for 13 years, indicating a commitment to shareholder returns. This is particularly relevant given the article’s focus on the company’s financial outlook. Additionally, the tip that BAH operates with a moderate level of debt provides context to the company’s financial stability, which could be a factor in its ability to navigate potential growth slowdowns mentioned in the analyst’s report.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips that could provide further insights into BAH’s market position and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Forex2 years agoForex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Forex2 years ago
Unbiased review of Pocket Option broker
- Cryptocurrency2 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Commodities2 years ago
Copper continues to fall in price on expectations of lower demand in China
- Forex2 years ago
The dollar is down again against major world currencies
